Allarity Therapeutics (DB:C6D0) - Prezzo delle azioni, notizie e analisi

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

C6D0 Panoramica delle azioni

A clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology.

Informazioni sull'azienda

C6D0 analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( €3M )

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Patrimonio netto negativo

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

+ 2 più rischi

Allarity Therapeutics, Inc. Concorrenti

bioXXmed

XTRA:T5O

€649.9k

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€31.6m

4SC

DB:VSC

€58.0m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Allarity Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.73
Massimo di 52 settimane	US$72.10
Minimo di 52 settimane	US$1.73
Beta	0
1Variazione di 1 mese	0%
Variazione a 3 mesi	-15.67%
Variazione di 1 anno	-97.01%
3Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	-99.59%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	C6D0	DE Biotechs	DE Mercato
7D	0%	2.6%	4.5%
1Y	-97.0%	-16.4%	13.4%

Ritorno vs Industria: C6D0 ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -22 % nell'ultimo anno.

Rendimento vs Mercato: C6D0 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 4.7 % nell'ultimo anno.

Volatilità dei prezzi

Is C6D0's price volatile compared to industry and market?
C6D0 volatility
C6D0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.8%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: Il prezzo delle azioni di C6D0 è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di C6D0 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2004	13	James Cullem	www.allarity.com

Allarity Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Allarity Therapeutics con la sua capitalizzazione di mercato?
C6D0 statistiche fondamentali
Capitalizzazione di mercato	€3.16m
Guadagni(TTM)	-€18.14m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-0.2x

Rapporto P/E

C6D0 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
C6D0 Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$19.76m
Guadagni	-US$19.75m

Ultimi guadagni dichiarati

Mar 31, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.03
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	-1,120.1%

Come si è comportato C6D0 nel lungo periodo?

Vedi performance storica e confronto

This company listing is no longer active

C6D0 Panoramica delle azioni

Premi

Analisi del rischio

Allarity Therapeutics, Inc. Concorrenti

XTRA:T5O

€649.9k

XTRA:CNW

€6.5m

XTRA:MDG1

€31.6m

DB:VSC

€58.0m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Allarity Therapeutics Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial

Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Recent updates

Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Allarity Therapeutics Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial

Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Allarity Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $0.947 million.

Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding

Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic

Allarity Therapeutics, Inc. Receives A Letter from Nasdaq Listing Qualifications Staff

Allarity Therapeutics Receives Notification from the Nasdaq Listing Qualifications Staff Regarding Non-Compliance with Listing Rule 5550(a)(2)

Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology

Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic (CDx) for Dovitinib in the Peer-Reviewed Journal PLOS ONE

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Allarity Therapeutics, Inc. Provides Nasdaq Compliance Update

Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of Ixempra®? in Metastatic Breast Cancer Patients

Allarity Therapeutics, Inc. announced that it expects to receive $0.35 million in funding from 3i, LP

Allarity Therapeutics Announces Reverse Stock Split of Common Stock to Bring it into Compliance with Nasdaq’s Listing Requirement Regarding Minimum Share Price

Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study

Allarity Therapeutics Announces Update on Delisting from The Nasdaq Stock Market

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

High number of new and inexperienced directors

Allarity Therapeutics Receives Notice from the Nasdaq

Allarity Therapeutics Regains Compliance with NASDAQ Listing Requirements

Allarity Therapeutics, Inc. Announces the Appointment of Jerry Mclaughlin as a Member of its Board of Directors, Effective October 1, 2022

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics, Inc., Annual General Meeting, Nov 04, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Announces Appointment of New Members to Its Board of Directors

Allarity Therapeutics, Inc. Announces Executive Leadership Transition

Allarity Therapeutics, Inc. Appoints Roberto Pili as Member of the Company’s Scientific Advisory Board

Allarity Therapeutics, Inc. Announces Impairment for the First Quarter Ended March 31, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics, Inc. announced delayed annual 10-K filing

Allarity Therapeutics, Inc. Receives Refusal to File Letters from U.S. FDA

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Allarity Therapeutics, Inc. Riepilogo dei fondamenti

0.0x

-0.2x

Guadagni e ricavi